OBJECTIVES: Increased sympathetic outflow, renin-angiotensin system (RAS) activity, and oxidative stress are critical mechanisms underlying the adverse cardiovascular effects of dietary salt excess. Nebivolol is a third-generation, highly selective β1-receptor blocker with RAS-reducing effects and additional antioxidant properties. This study evaluated the hypothesis that nebivolol reduces salt-induced cardiac remodeling and dysfunction in spontaneous hypertensive rats (SHRs) by suppressing cardiac RAS and oxidative stress. METHODS: Male SHRs (8 weeks of age) were given an 8% high salt diet (HSD; n = 22), whereas their age-matched controls (n = 10) received standard chow. In a subgroup of HSD rats (n = 11), nebivolol was given at a dose of 10 mg/kg per day by gastric gavage. RESULTS: After 5 weeks, HSD exacerbated hypertension as well as increased left-ventricular weight and collagen deposition while impairing left-ventricular relaxation. Salt-induced cardiac remodeling and dysfunction were associated with increased plasma renin concentration (PRC), cardiac angiotensin II immunostaining, and angiotensin-converting enzyme (ACE)/ACE2 mRNA and activity ratio. HSD also increased cardiac 3-nitrotyrosine staining indicating enhanced oxidative stress. Nebivolol treatment did not alter the salt-induced increase in arterial pressure, left-ventricular weight, and cardiac dysfunction but reduced PRC, cardiac angiotensin II immunostaining, ACE/ACE2 ratio, oxidative stress, and fibrosis. CONCLUSIONS: Our data suggest that nebivolol, in a blood pressure-independent manner, ameliorated cardiac oxidative stress and associated fibrosis in salt-loaded SHRs. The beneficial effects of nebivolol may be attributed, at least in part, to the decreased ACE/ACE2 ratio and consequent reduction of cardiac angiotensin II levels.
OBJECTIVES: Increased sympathetic outflow, renin-angiotensin system (RAS) activity, and oxidative stress are critical mechanisms underlying the adverse cardiovascular effects of dietary salt excess. Nebivolol is a third-generation, highly selective β1-receptor blocker with RAS-reducing effects and additional antioxidant properties. This study evaluated the hypothesis that nebivolol reduces salt-induced cardiac remodeling and dysfunction in spontaneous hypertensiverats (SHRs) by suppressing cardiac RAS and oxidative stress. METHODS: Male SHRs (8 weeks of age) were given an 8% high salt diet (HSD; n = 22), whereas their age-matched controls (n = 10) received standard chow. In a subgroup of HSDrats (n = 11), nebivolol was given at a dose of 10 mg/kg per day by gastric gavage. RESULTS: After 5 weeks, HSD exacerbated hypertension as well as increased left-ventricular weight and collagen deposition while impairing left-ventricular relaxation. Salt-induced cardiac remodeling and dysfunction were associated with increased plasma renin concentration (PRC), cardiac angiotensin II immunostaining, and angiotensin-converting enzyme (ACE)/ACE2 mRNA and activity ratio. HSD also increased cardiac 3-nitrotyrosine staining indicating enhanced oxidative stress. Nebivolol treatment did not alter the salt-induced increase in arterial pressure, left-ventricular weight, and cardiac dysfunction but reduced PRC, cardiac angiotensin II immunostaining, ACE/ACE2 ratio, oxidative stress, and fibrosis. CONCLUSIONS: Our data suggest that nebivolol, in a blood pressure-independent manner, ameliorated cardiac oxidative stress and associated fibrosis in salt-loaded SHRs. The beneficial effects of nebivolol may be attributed, at least in part, to the decreased ACE/ACE2 ratio and consequent reduction of cardiac angiotensin II levels.
Authors: William J Welch; Margarida Mendonca; Jonathan Blau; Alex Karber; Kathryn Dennehy; Kinjal Patel; Yuen-Sum Lao; Pedro A José; Christopher S Wilcox Journal: Kidney Int Date: 2005-07 Impact factor: 10.612
Authors: Carlos M Ferrario; Jewell Jessup; Mark C Chappell; David B Averill; K Bridget Brosnihan; E Ann Tallant; Debra I Diz; Patricia E Gallagher Journal: Circulation Date: 2005-05-16 Impact factor: 29.690
Authors: David J Grieve; Jonathan A Byrne; Anjana Siva; Joanne Layland; Sofian Johar; Alison C Cave; Ajay M Shah Journal: J Am Coll Cardiol Date: 2006-01-26 Impact factor: 24.094
Authors: Ibrahim N Mansour; Adam P Bress; Vicki Groo; Sahar Ismail; Grace Wu; Shitalben R Patel; Julio D Duarte; Rick A Kittles; Thomas D Stamos; Larisa H Cavallari Journal: J Card Fail Date: 2015-12-22 Impact factor: 5.712
Authors: Frank H Mose; Janni M Jensen; Safa Therwani; Jesper Mortensen; Annebirthe B Hansen; Jesper N Bech; Erling B Pedersen Journal: Br J Clin Pharmacol Date: 2015-06-05 Impact factor: 4.335
Authors: Julieta S Del Mauro; Paula D Prince; Yanina Santander Plantamura; Miguel A Allo; Luciano Parola; Nahuel Fernandez Machulsky; Marcela A Morettón; Eliana P Bin; Germán E González; Facundo M Bertera; Andrea Carranza; Gabriela Berg; Carlos A Taira; Martín Donato; Diego A Chiappetta; Ariel H Polizio; Christian Höcht Journal: Hypertens Res Date: 2021-02-22 Impact factor: 3.872
Authors: Sheila K Patel; Elena Velkoska; Melanie Freeman; Bryan Wai; Terase F Lancefield; Louise M Burrell Journal: Front Physiol Date: 2014-06-24 Impact factor: 4.566